Clinical Trials Directory

Trials / Terminated

TerminatedNCT00397319

Growth Hormone's Effect on the Cardiovascular System

The Role of Growth Hormone in Cardiovascular Health

Status
Terminated
Phase
Study type
Observational
Enrollment
26 (planned)
Sponsor
Vanderbilt University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.

Detailed description

Growth hormone deficiency (GHD) is associated with increased cardiovascular morbidity and mortality. The effects of such a deficiency include decreased exercise capacity and tolerance, impaired cardiac function, a central fat redistribution, increased peripheral arterial resistance, and an unfavorable lipid profile. These effects have been found to be reversed with appropriate replacement therapy with recombinant human growth hormone. We plan to utilize several experimental systems to further investigate the role of growth hormone (GH) in maintaining cardiovascular health. In particular, we would like to further understand the interaction of GH with Plasminogen-activator-inhibitor-1 (a major activator of the fibrinolytic system) as well as the role of GH in the maintenance of vascular function.

Conditions

Interventions

TypeNameDescription
DRUGGrowth Hormone

Timeline

Start date
2005-08-01
Completion
2006-12-01
First posted
2006-11-09
Last updated
2007-07-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00397319. Inclusion in this directory is not an endorsement.